Clinical Trials Logo

Colitis, Ulcerative clinical trials

View clinical trials related to Colitis, Ulcerative.

Filter by:

NCT ID: NCT00355901 Terminated - Ulcerative Colitis Clinical Trials

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Start date: September 2006
Phase: Phase 2
Study type: Observational

To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.

NCT ID: NCT00349388 Terminated - Ulcerative Colitis Clinical Trials

Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

Start date: July 2006
Phase: N/A
Study type: Interventional

To determine whether once a day administration of Mesalamine is at least as safe and efficacious and administration of multiple doses a day in preventing clinical relapse of ulcerative colitis in children and adolescence.

NCT ID: NCT00317356 Terminated - Colitis, Ulcerative Clinical Trials

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of OPC-6535 (tetomilast) and to determine its optimal dose by once-daily oral administration at 0, 12.5, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic acid (5-ASA) in patients with active ulcerative colitis.

NCT ID: NCT00307827 Terminated - Ulcerative Colitis Clinical Trials

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.

NCT ID: NCT00296556 Terminated - Ulcerative Colitis Clinical Trials

Therapeutic Study of ONO-4819CD for Ulcerative Colitis

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether ONO-4819CD is safe and effective in the treatment of mild to moderate ulcerative colitis.

NCT ID: NCT00279435 Terminated - Ulcerative Colitis Clinical Trials

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Start date: August 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.

NCT ID: NCT00279422 Terminated - Ulcerative Colitis Clinical Trials

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Start date: February 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.

NCT ID: NCT00268164 Terminated - Ulcerative Colitis Clinical Trials

Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the lactic acid bacteria " Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)" is effective as maintenance treatment in ulcerative colitis.

NCT ID: NCT00254618 Terminated - Ulcerative Colitis Clinical Trials

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.

Start date: October 2005
Phase: Phase 1
Study type: Interventional

The purpose of this randomized, open-label, parallel-group study is to determine how the body absorbs and eliminates mesalamine following administration of either 30 mg/kg/day, 60 mg/kg/day or 90 mg/kg/day as 400 mg delayed-release tablets given every 12 hours of 28 days to children and adolescents with active ulcerative colitis.

NCT ID: NCT00209287 Terminated - Ulcerative Colitis Clinical Trials

Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis

Start date: June 2005
Phase: Phase 4
Study type: Interventional

Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day. Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at the inclusion. Signed informed consent form.